Immunopotentiating compounds
    7.
    发明授权
    Immunopotentiating compounds 有权
    免疫增强化合物

    公开(公告)号:US08063063B2

    公开(公告)日:2011-11-22

    申请号:US12294237

    申请日:2007-03-23

    CPC分类号: C07D471/14 C07D471/04

    摘要: The invention provides novel compositions comprising Imidazopyridine compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).

    摘要翻译: 本发明提供包含咪唑并吡啶化合物的新型组合物。 还提供了以有效量施用组合物以增强受试者的免疫应答的方法。 进一步提供了组合物与(一种或多种)其它试剂组合施用的新组合物和方法。

    Nucleic acid vectors for immunization
    9.
    发明授权
    Nucleic acid vectors for immunization 失效
    用于免疫的核酸载体

    公开(公告)号:US07541180B2

    公开(公告)日:2009-06-02

    申请号:US10479649

    申请日:2002-05-30

    申请人: Nicholas Valiante

    发明人: Nicholas Valiante

    IPC分类号: C12N15/00 C07H21/02 C07H21/00

    摘要: A dimeric protein comprising a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a targeting domain, a leucine zipper domain, and an antigen; and wherein the second fusion protein comprises a targeting domain, a leucine zipper domain, and optionally an antigen. Nucleic acid vectors encoding proteins of the invention are provided, particularly for use in nucleic acid vaccination.

    摘要翻译: 包含第一融合蛋白和第二融合蛋白的二聚蛋白,其中所述第一融合蛋白包含靶向结构域,亮氨酸拉链结构域和抗原; 并且其中所述第二融合蛋白包含靶向结构域,亮氨酸拉链结构域和任选的抗原。 提供编码本发明蛋白质的核酸载体,特别是用于核酸疫苗接种。

    Compounds for immunopotentiation
    10.
    发明申请
    Compounds for immunopotentiation 审中-公开
    化合物免疫增强

    公开(公告)号:US20100226931A1

    公开(公告)日:2010-09-09

    申请号:US11630551

    申请日:2005-06-24

    IPC分类号: A61K39/00 A61P35/04

    摘要: Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed. In a preferred embodiment benzopyrimidine derivatives such as ZD-6474, MLN-518, lapatinib, gefitinib or erlotinib are used.

    摘要翻译: 刺激免疫反应并用3,4-二(1H-吲哚-3-基)-1H-吡咯-2,5-二酮,星形孢菌素类似物,衍生化哒嗪,色烯-4-酮,吲哚啉酮 ,喹唑啉,核苷类似物和其他小分子。 在优选的实施方案中,使用苯并嘧啶衍生物如ZD-6474,MLN-518,拉帕替尼,吉非替尼或厄洛替尼。